Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose--is more better?

Affiliations

Comment

Peter A Calabresi. Nat Clin Pract Neurol. 2007 Oct.

. 2007 Oct;3(10):540-1.

doi: 10.1038/ncpneuro0612. Epub 2007 Sep 4.

¹ Johns Hopkins Multiple Sclerosis Center, Baltimore, MD, USA. pcalabr1@jhmi.edu

No abstract available

Comment on

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group. Cohen JA, et al. Neurology. 2007 Mar 20;68(12):939-44. doi: 10.1212/01.wnl.0000257109.61671.06. Neurology. 2007. PMID: 17372130 Clinical Trial.

Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ, Cowan BJ, Moore GR, Hashimoto SA. Ball NJ, et al. J Cutan Pathol. 2008 Apr;35(4):407-10. doi: 10.1111/j.1600-0560.2007.00819.x. J Cutan Pathol. 2008. PMID: 18333902
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Johnson KP, Due DL. Johnson KP, et al. Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):205-14. doi: 10.1586/erp.09.20. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19527092 Review.
[Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B. Brochet B. Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. Rev Neurol (Paris). 2008. PMID: 18790510 French.
Lessons from randomised direct comparative trials.
Achiron A, Fredrikson S. Achiron A, et al. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S19-24. doi: 10.1016/S0022-510X(09)70007-3. J Neurol Sci. 2009. PMID: 19200860 Review.
Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau T. Moreau T. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S12-5. doi: 10.1016/S0022-510X(09)70005-X. J Neurol Sci. 2009. PMID: 19200858 Review.